Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Taiwanese (TAIEX) Pharma Industry Analysis

UpdatedApr 03, 2026
DataAggregated Company Financials
Companies59
  • 7D2.9%
  • 3M-17.8%
  • 1Y-4.4%
  • YTDn/a

In the last week, the Pharma industry is up 2.9%, with Caliway Biopharmaceuticals up 12%. In the same time, Pharmasaga was down 9.3%. In contrast, the industry has lost 4.4% in the last 12 months. As for the next few years, earnings are expected to grow by 69% per annum.

Industry Valuation and Performance

Has the Taiwanese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 03 Apr 2026NT$609.8bNT$119.2bNT$20.7b15x29.4x5.1x
Sun, 01 Mar 2026NT$762.9bNT$119.4bNT$12.4b17x61.4x6.4x
Tue, 27 Jan 2026NT$790.5bNT$119.3bNT$12.4b17.6x63.6x6.6x
Thu, 25 Dec 2025NT$742.3bNT$118.0bNT$12.3b16.7x60.3x6.3x
Sat, 22 Nov 2025NT$675.9bNT$118.0bNT$12.1b16.1x55.8x5.7x
Mon, 20 Oct 2025NT$794.0bNT$118.3bNT$9.6b16.2x82.6x6.7x
Wed, 17 Sep 2025NT$833.0bNT$118.4bNT$10.2b16.4x81.5x7x
Fri, 15 Aug 2025NT$712.0bNT$117.6bNT$11.5b19x61.8x6.1x
Sun, 13 Jul 2025NT$655.0bNT$116.0bNT$14.3b18.5x45.8x5.6x
Tue, 10 Jun 2025NT$634.2bNT$115.9bNT$14.3b19.2x44.5x5.5x
Thu, 08 May 2025NT$559.1bNT$113.6bNT$10.6b18.6x52.8x4.9x
Sat, 05 Apr 2025NT$596.0bNT$112.8bNT$10.8b18.3x55.1x5.3x
Mon, 03 Mar 2025NT$674.8bNT$109.3bNT$11.4b23.5x59x6.2x
Wed, 29 Jan 2025NT$612.0bNT$109.3bNT$11.4b21.7x53.5x5.6x
Fri, 27 Dec 2024NT$597.1bNT$109.3bNT$11.4b22.1x52.2x5.5x
Sun, 24 Nov 2024NT$628.8bNT$109.2bNT$11.5b23x54.8x5.8x
Tue, 22 Oct 2024NT$629.4bNT$104.7bNT$8.9b27.2x70.4x6x
Thu, 19 Sep 2024NT$623.7bNT$104.7bNT$8.9b24.6x69.7x6x
Sat, 17 Aug 2024NT$659.5bNT$103.9bNT$9.0b27.1x73.4x6.3x
Mon, 15 Jul 2024NT$682.8bNT$100.5bNT$6.8b32x100x6.8x
Wed, 12 Jun 2024NT$635.6bNT$100.4bNT$7.1b29.9x88.9x6.3x
Fri, 10 May 2024NT$611.0bNT$101.8bNT$9.4b25.8x65.3x6x
Sun, 07 Apr 2024NT$700.0bNT$101.5bNT$9.2b26.7x76x6.9x
Tue, 05 Mar 2024NT$657.5bNT$102.0bNT$8.3b23.9x79.4x6.4x
Thu, 01 Feb 2024NT$592.4bNT$101.9bNT$7.8b23.9x76x5.8x
Sat, 30 Dec 2023NT$580.1bNT$101.9bNT$7.8b23.9x74.4x5.7x
Mon, 27 Nov 2023NT$570.2bNT$101.6bNT$7.7b22.4x74.5x5.6x
Wed, 25 Oct 2023NT$534.6bNT$101.7bNT$9.6b20.7x55.6x5.3x
Fri, 22 Sep 2023NT$543.2bNT$101.7bNT$9.6b21.9x56.5x5.3x
Sun, 20 Aug 2023NT$543.8bNT$101.7bNT$9.6b21.5x56.4x5.3x
Tue, 18 Jul 2023NT$584.2bNT$98.7bNT$10.1b17.1x58x5.9x
Thu, 15 Jun 2023NT$577.1bNT$98.6bNT$10.1b16.9x57.4x5.9x
Sat, 13 May 2023NT$561.4bNT$92.2bNT$8.6b19.8x65.1x6.1x
Mon, 10 Apr 2023NT$587.2bNT$91.2bNT$8.5b21.1x69.1x6.4x
Price to Earnings Ratio

69.1x


Total Market Cap: NT$587.2bTotal Earnings: NT$8.5bTotal Revenue: NT$91.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Taiwanese Pharma Industry Price to Earnings3Y Average 64.6x202420252026
Current Industry PE
  • Investors are pessimistic on the Taiwanese Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 29.4x which is lower than its 3-year average PE of 64.6x.
  • The 3-year average PS ratio of 6.0x is higher than the industry's current PS ratio of 5.1x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 35% per year over the last three years.
  • Revenues for these companies have grown 9.4% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Taiwanese Pharma compare with similar industries?

TW Market-2.24%
Healthcare0.20%
Pharma2.88%
Pharma2.88%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
6919 Caliway BiopharmaceuticalsNT$95.8011.9%
+NT$15.8b		22.7%PS3911.3x
1795 Lotus PharmaceuticalNT$216.003.6%
+NT$2.0b		-6.9%PE12x
1789 ScinoPharm TaiwanNT$22.658.9%
+NT$1.5b		7.3%PE130.8x
4743 Oneness BiotechNT$54.604.8%
+NT$1.2b		-22.0%PS202.3x
7754 AnnJi PharmaceuticalNT$67.909.0%
+NT$525.7m		244.7%PS267.3x

Latest News

6919
NT$95.80
Caliway Biopharmaceuticals
7D
11.9%
1Y
22.7%
1795
NT$216.00
Lotus Pharmaceutical
7D
3.6%
1Y
-6.9%

1795: Higher Growth Assumptions And Lower P/E Multiple Will Drive Future Upside

Analysts have reduced their fair value estimate for Lotus Pharmaceutical from NT$600.00 to NT$500.00, reflecting updated assumptions around revenue growth, profit margins and a lower future P/E multiple. Valuation Changes Fair Value: Reduced from NT$600.00 to NT$500.00, a cut of roughly 17%.
7829
NT$43.80
Yoda Pharmaceuticals
7D
-7.5%
1Y
n/a
6620
NT$67.50
Handa Pharmaceuticals
7D
-2.2%
1Y
-18.7%
3705
NT$55.50
YungShin Global Holding
7D
2.6%
1Y
-5.6%
6472
NT$449.00
Bora Pharmaceuticals
7D
-1.3%
1Y
-22.2%

6472: Renewed GSK Manufacturing Agreement Will Support Long Term Earnings Power

Analysts have inched up their price target on Bora Pharmaceuticals to NT$741.35 from NT$741.02, citing updated assumptions that combine a higher revenue growth outlook of 29.58% with a slightly stronger profit margin of 20.74% and a modestly lower future P/E of 13.69. What's in the News Bora Pharmaceuticals has scheduled a board meeting on March 11, 2026, to review the 2025 fourth quarter consolidated financial statement (Key Developments).
4743
NT$54.60
Oneness Biotech
7D
4.8%
1Y
-22.0%
1271
NT$67.10
SunWay Biotech
7D
10.2%
1Y
1.7%
7754
NT$67.90
AnnJi Pharmaceutical
7D
9.0%
1Y
244.7%
6785
NT$167.00
Alar Pharmaceuticals
7D
-2.9%
1Y
25.6%
4130
NT$34.05
Genovate Biotechnology
7D
6.4%
1Y
60.8%
4105
NT$73.60
TTY Biopharm
7D
-1.1%
1Y
-2.8%
1789
NT$22.65
ScinoPharm Taiwan
7D
8.9%
1Y
7.3%
6467
NT$125.50
Taho Pharmaceuticals
7D
-7.0%
1Y
96.4%
7878
NT$272.50
Pharmasaga
7D
-9.3%
1Y
n/a
6535
NT$142.50
Lumosa Therapeutics
7D
-5.3%
1Y
-19.7%